Nurix Therapeutics (NRIX) FCF Margin (2019 - 2026)
Nurix Therapeutics (NRIX) reported FCF Margin of 1166.97% for Q1 2026, down 82945.0% year-over-year from N/an in Q1 2025, and down 98.76% quarter-over-quarter from 587.13% in Q4 2025.
Nurix Therapeutics (NRIX) FCF Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of FCF Margin data on file, last reported at 1166.97% in Q1 2026.
- FCF Margin for Q1 2026 came in at 1166.97%, down 82945.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 641.68% (down 28840.0% YoY), and the FY2025 annual result was 313.73%, up 1966.0% from the prior year.
- FCF Margin retreated to 1166.97% in Q1 2026 per NRIX's latest filing, from 587.13% in the prior quarter.
- Over five years, FCF Margin peaked at 210.26% in Q4 2023 and troughed at 1166.97% in Q1 2026.
- A 5-year average of 401.48% and a median of 382.84% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin surged 76461 bps in 2023, then plunged 82945 bps in 2026.
- A 5-year view of FCF Margin shows it stood at 554.36% in 2022, then surged by 138 bps to 210.26% in 2023, then plunged by 282 bps to 382.84% in 2024, then slumped by 53 bps to 587.13% in 2025, then sank by 99 bps to 1166.97% in 2026.
- Business Quant data shows NRIX's FCF Margin at 1166.97% in Q1 2026, 587.13% in Q4 2025, and 740.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -1,166.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -1,166.97% |
| Nov 30, 2025 | -587.13% |
| Aug 31, 2025 | -740.09% |
| May 31, 2025 | -420.31% |
| Feb 28, 2025 | -337.52% |
| Nov 30, 2024 | -382.84% |
| Aug 31, 2024 | -376.65% |
| May 31, 2024 | -320.48% |
| Feb 29, 2024 | -270.33% |
| Nov 30, 2023 | 210.26% |
| Aug 31, 2023 | -237.74% |
| May 31, 2023 | -62.71% |
| Feb 28, 2023 | -399.91% |
| Nov 30, 2022 | -554.36% |
| Aug 31, 2022 | -420.17% |
| May 31, 2022 | -292.16% |
| Feb 28, 2022 | -466.03% |
| Nov 30, 2021 | -440.47% |
| Aug 31, 2021 | -294.62% |
| May 31, 2021 | -443.86% |